Israel - Ibrani - Ministry of Health

bayer israel ltd - recombinant human coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - recombinant human coagulation factor viii 2000 iu - coagulation factor viii

Israel - Ibrani - Ministry of Health

bayer israel ltd - recombinant human coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - recombinant human coagulation factor viii 250 iu - coagulation factor viii

Israel - Ibrani - Ministry of Health

bayer israel ltd - recombinant human coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - recombinant human coagulation factor viii 500 iu - coagulation factor viii

Israel - Ibrani - Ministry of Health

csl behring ltd., israel - coagulation factor ii (human); coagulation factor ix (human- rfixfc); coagulation factor vii (human); coagulation factor x (human); protein c; protein s antigen - אבקה וממס להכנת תמיסה להזרקה - coagulation factor ii (human) 200 - 480 iu; coagulation factor vii (human) 100 - 250 iu; coagulation factor ix (human- rfixfc) 200 - 310 iu; coagulation factor x (human) 220 - 600 iu; protein c 150 - 450 iu; protein s antigen 120 - 380 iu - coagulation factor ix, ii, vii and x in combination - coagulation factor ix, ii, vii and x in combination - -treatment and perioperative prophylaxis of bleedings in acquired deficiency of the prothrombin complex coagulation factors, such as deficiency caused by treatment with vitamin k antagonists, or in case of overdose of vitamin k antagonists, when rapid correction of the deficiency is required.

Israel - Ibrani - Ministry of Health

mediline ltd. - factor viii recombinant 500 iu/dose - lyophilized powder for injection - coagulation factor viii - for the treatment of classical hemophilia ( hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor viii.

Israel - Ibrani - Ministry of Health

mediline ltd. - factor viii recombinant 1000 iu/dose - lyophilized powder for injection - coagulation factor viii - for the treatment of classical hemophilia ( hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor viii.

Israel - Ibrani - Ministry of Health

teva medical marketing ltd. - factor viii human coagulation 250 iu/vial - powder for solution for injection - coagulation factor viii - treatment and prophylaxis of bleeding in patients with congenital (haemophilia a) or acquired factor viii deficiency. von willebrand's disease with factor viii deficiency.

Israel - Ibrani - Ministry of Health

teva medical marketing ltd. - factor viii human coagulation vhsd treated 500 iu/vial - powder for solution for injection - coagulation factor viii - treatment and prophylaxis of bleeding in patients with congenital (haemophilia a) or acquired factor viii deficiency. von willebrand's disease with factor viii deficiency.

Israel - Ibrani - Ministry of Health

teva medical marketing ltd. - factor viii human coagulation 1000 iu/vial - powder for solution for injection - coagulation factor viii - treatment and prophylaxis of bleeding in patients with congenital (haemophilia a) or acquired factor viii deficiency. von willebrand's disease with factor viii deficiency.

Israel - Ibrani - Ministry of Health

bayer israel ltd - antihemophilic factor (recombinant) sucrose - אבקה להכנת תמיסה לזריקה - antihemophilic factor (recombinant) sucrose 500 iu/vial - blood coagulation factors - for the treatment of classical hemophilia (hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor viii.routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with severe hemophilia a with no pre-existing joint damage. kogenate fs is not indicated for the treatment of von willebrand’s disease.